Skip to main content

Table 2 Change in HbA1c in new users of high-potency statins or low-potency statins as the control group

From: Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus

 

High-potency statins

Atorvastatin

Pitavastatin

Rosuvastatin

Low-potency statins

With diabetes

 Number of patients

153

47

42

64

22

 Mean period (days)a

209

166

189

254

231

 HbA1c (%), mean ± SD

     

  Before

7.18 ± 1.37

7.03 ± 1.31

7.57 ± 1.64

7.03 ± 1.17

6.95 ± 1.92

  After

7.57 ± 1.58

7.25 ± 1.21

8.11 ± 1.79

7.45 ± 1.61

7.25 ± 1.29

  Difference

0.39 ± 1.27

0.21 ± 0.75

0.54 ± 1.61

0.42 ± 1.32

0.30 ± 0.94

p-value

0.0002

0.05

0.04

0.01

0.15

Without diabetes

 Number of patients

165

49

31

85

10

 Mean period (days)a

239

212

310

229

236

 HbA1c (%), mean ± SD

     

  Before

5.78 ± 0.38

5.76 ± 0.42

5.69 ± 0.24

5.81 ± 0.41

5.80 ± 0.47

  After

5.92 ± 0.45

5.95 ± 0.45

5.90 ± 0.48

5.92 ± 0.45

6.07 ± 0.58

  Difference

0.15 ± 0.31

0.19 ± 0.31

0.21 ± 0.46

0.10 ± 0.22

0.27 ± 0.18

p-value

<0.0001

0.0001

0.02

<0.0001

0.001

p-valueb

0.02

0.89

  1. Abbreviations: SD standard deviation
  2. aDifference between statin start date and HbA1c measurement date
  3. bComparison of differences in HbA1c between diabetes and non-diabetes